Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full ...

Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

Pharming Group ( (PHAR) ) has issued an announcement.

Leiden, the Netherlands, February 20, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease. At the ...

6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...

A pharming attack tries to redirect a website’s traffic to a fake website controlled by the attacker, usually for the purpose of collecting sensitive information from victims or installing malware on ...